Clinical Trials in Lafayette, Indiana
17 recruiting
Showing 1–16 of 16 trials
Recruiting
Phase 3
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Lung Non-Small Cell Carcinoma+3 more
National Cancer Institute (NCI)1,210 enrolled1151 locationsNCT04267848
Recruiting
Phase 3
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC780 enrolled260 locationsNCT06312137
Recruiting
Phase 3
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Endometrial CarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Dedifferentiated Carcinoma+5 more
National Cancer Institute (NCI)360 enrolled408 locationsNCT05256225
Recruiting
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
Lumbar Spinal Stenosis
Stryker Instruments8,000 enrolled2262 locationsNCT03072927
Recruiting
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Malignant Solid Neoplasm
SWOG Cancer Research Network2,062 enrolled849 locationsNCT04871542
Recruiting
Phase 3
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC675 enrolled149 locationsNCT07190248
Recruiting
Phase 3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Triple-Negative Breast Cancer
Gilead Sciences1,514 enrolled339 locationsNCT05633654
Recruiting
Not Applicable
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Anatomic Stage IV Breast Cancer AJCC v8Prognostic Stage IV Breast Cancer AJCC v8HER2/Neu Negative+3 more
SWOG Cancer Research Network739 enrolled723 locationsNCT03723928
Recruiting
Phase 1
An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
CancerSolid Tumor, AdultCancer, Metastatic+3 more
Shenzhen Ionova Life Sciences Co., Ltd.78 enrolled3 locationsNCT04443088
Recruiting
Phase 1
Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies
Relapsed or Refractory Hematologic Malignancies
Vanda Pharmaceuticals42 enrolled11 locationsNCT03838926
Recruiting
Not Applicable
Pilot Randomized Clinical Trial of Informational Support Versus Spiritual Care
Stage IV Lung CancerStage IV Gastrointestinal Cancer
Indiana University36 enrolled4 locationsNCT07176559
Recruiting
Phase 2
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
Solid Tumors
Hoffmann-La Roche920 enrolled163 locationsNCT04589845
Recruiting
Phase 1Phase 2
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
Cancer
MBrace Therapeutics130 enrolled17 locationsNCT06014658
Recruiting
Phase 3
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Recurrent Breast CarcinomaStage IV Breast Cancer AJCC v6 and v7Cardiotoxicity+2 more
SWOG Cancer Research Network491 enrolled590 locationsNCT03418961
Recruiting
Phase 1Phase 2
A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors
Advanced Solid TumorNSCLC
Shanghai Huaota Biopharmaceutical Co., Ltd.80 enrolled4 locationsNCT05417321
Recruiting
Not Applicable
Coflex PS3 Actual Conditions for Use Study
Spinal Stenosis Lumbar
Xtant Medical300 enrolled19 locationsNCT02555280